Does Rallies show Form 4 insider transactions for SNGX?

Yes. Rallies tracks SNGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SNGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SNGX. It does not provide personalized investment advice.

SNGX (Soligenix, Inc. Common Stock) Stock Analysis - Insider Trades

Soligenix, Inc. Common Stock (SNGX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNGX trades at $0.39 with a market cap of $6.06M and a P/E ratio of -0.17. SNGX moved +3.22% today. Year to date, SNGX is -72.88%; over the trailing twelve months it is -80.31%. Its 52-week range spans $0.28 to $6.23. Analyst consensus is buy with an average price target of $1.50. Rallies surfaces SNGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SNGX stock inside the company?

Recent SNGX insider activity includes SCHABER CHRISTOPHER J bought 15.13K, Straube Richard bought 8.00K, SCHABER CHRISTOPHER J bought 20.00K, SCHABER CHRISTOPHER J bought 7.00K, and Guarino Jonathan L. bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SNGX Key Metrics

Key financial metrics for SNGX
Metric	Value
Price	$0.39
Market Cap	$6.06M
P/E Ratio	-0.17
EPS	$-2.14
Dividend Yield	0.00%
52-Week High	$6.23
52-Week Low	$0.28
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-11.08M
Gross Margin	0.00%

Recent SNGX Insider Trades

SCHABER CHRISTOPHER J bought 15.13K (~$20.00K) on Oct 2, 2025.
Straube Richard bought 8.00K (~$4.00K) on May 18, 2022.
SCHABER CHRISTOPHER J bought 20.00K (~$8.87K) on May 18, 2022.
SCHABER CHRISTOPHER J bought 7.00K (~$5.18K) on Dec 17, 2021.
Guarino Jonathan L. bought 1.00K (~$700) on Dec 15, 2021.

Latest SNGX News

Soligenix Halts Phase 3 HyBryte Trial for Futility, Holds $6M Cash Runway — May 8, 2026
European Commission Grants SGX945 Orphan Status for Behçet’s Disease — Apr 20, 2026
HyBryte Achieves 60% Success Rate vs Valchlor’s 20% with No Adverse Events — Apr 2, 2026
Soligenix posts $11.1M net loss, Q2 2026 interim Phase 3 analysis planned — Mar 31, 2026
Soligenix Readies Phase 3 HyBryte FLASH2 CTCL Readout and SGX945 Progress — Mar 25, 2026

SNGX Analyst Consensus

1 analysts cover SNGX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.50.

Common questions about SNGX

Who is trading SNGX stock inside the company?: Recent SNGX insider activity includes SCHABER CHRISTOPHER J bought 15.13K, Straube Richard bought 8.00K, SCHABER CHRISTOPHER J bought 20.00K, SCHABER CHRISTOPHER J bought 7.00K, and Guarino Jonathan L. bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SNGX?: Yes. Rallies tracks SNGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SNGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SNGX. It does not provide personalized investment advice.